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Moraxella catarrhalis is a signiﬁcant cause of respiratory tract infection against which a
vaccine is sought. Several outer membrane proteins are currently under investigation as
potential vaccine antigens, including the porin M35. We have previously shown that the
third external loop of M35 was immunodominant over the remainder of the protein for
antibody produced in mice against the refolded recombinant protein. However, as this
loop is predicted to fold inside the porin channel we also predicted that it would not be
accessible to these antibodies when M35 is expressed on the surface of the bacteria in
its native conformation.This study investigated the functional activity of antibodies against
M35 and those speciﬁc for the loop 3 region of M35 in vitro and in vivo. Antisera from
mice immunized with M35 or the loop 3-deletion, M35loop3−, recombinant proteins were
not bactericidal but did have enhanced opsonic activity, whereas antibodies raised against
the loop 3 peptide were not opsoniszing indicating that the immunodominant loop 3 of
M35 was not accessible to antibody as we had previously predicted. Mucosal immuniza-
tion with M35, M35 that had an antigenically altered loop 3 [M35(ID78)] and M35loop3−
enhanced the clearance of M. catarrhalis from the lungs of mice challenged with live
M. catarrhalis. The in vivo clearance of bacteria in the mice with the M35-derived protein
constructs correlated signiﬁcantly (p <0.001) with the opsonic activity assessed an in vitro
opsonophagocytosis assay.This study has demonstrated that the immunodominant B-cell
epitope to loop 3 of the M. catarrhalis outer membrane protein M35 is not associated with
immune protection and that M35-speciﬁc antibodies are not bactericidal but are opsonisz-
ing. The opsoniszing activity correlated with in vivo clearance of the bacteria suggesting
that opsoniszing antibody may be a good correlate of immune protection.
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INTRODUCTION
Moraxella catarrhalis is a Gram-negative bacterium that is often
the causual organism for respiratory tract infections such as otitis
media, sinusitis, and exacerbations of chronic obstructive pul-
monary disease (COPD; Murphy, 1996; Karalus and Campagnari,
2000; Verduin et al., 2002). On rare occasions this bacterium can
cause more serious diseases such as meningitis and septicaemia
(Meyer et al., 1995; Daoud et al., 1996). Additionally, the presence
of M. catarrhalis appears to inﬂuence the pathogenicity of other
respiratory pathogens, such as Haemophilus inﬂuenzae (Arm-
bruster et al.,2010) andStreptococcus pneumoniae (Krishnamurthy
et al., 2009). A vaccine against M. catarrhalis is sought and a num-
ber of outer membrane proteins are currently being characterized
and evaluated for their potential as vaccine antigens (Murphy,
2005, 2009; Massa et al., 2009; Mawas et al., 2009). We have previ-
ously reported the characterizationof anOMP fromM. catarrhalis,
designatedM35, thatwe are investigating for its functional role and
potential as a vaccine antigen.
Our initial characterization of M35 suggested that it possesses
the desired characteristics of a vaccine antigen in that it is highly
conserved, surface exposed, and immunogenic in an animalmodel
(Easton et al., 2005). Subsequent studies conﬁrmed a high level
of conservation of M35 across strains, as well as demonstrating
an important role for M35 in resistance to aminopenicillins (Jet-
ter et al., 2009) and involvement in several stress responses. M35
shares homology with the family of outer membrane porins and is
likely to conform to the usual tertiary structure of porins in which
the third of eight external loops folds into the lumen of a channel
formed by 16 anti-parallel β-sheets (Seshadri et al., 1998). In the
predicted structure of M35 the third external loop is one of three
loops that are much longer than the other loops (Figure 1). M35
contains an immunodominant epitope in the third external loop
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and we hypothesized that if loop 3 folded into the porin channel
then it would not be accessible to antibody (Easton et al., 2005). By
directing the majority of the antibody response against an inac-
cessible epitope, the bacteria could protect this protein from the
host’s immune system and subsequent immunological selective
pressure. This could potentially explain why M35 is so highly con-
served, while other similar OMPs tend to have variable surface
regions in response to selective pressure from the host’s immune
system (Haase et al., 1991; Bash et al., 1995; Schirmer, 1998; Mes
and van Putten, 2007).
M35 was also shown to have epitopes that are accessible to anti-
body binding on the surface of the bacterium (Easton et al., 2005).
If the above hypothesis is correct, these surface epitopes would not
include loop 3. As part of identifying the speciﬁcity of antibody
to loop 3 it was also found that a single amino acid substitution
in loop 3 (in the isolate ID78LN266) was sufﬁcient to signiﬁcantly
reduce recognition of M35 by antibody. In this context, both the
conformational signiﬁcance of the loop and single point muta-
tions within immunodominant loop regions have been identiﬁed
as affecting antibody binding for the P2 porin of non-typeable
Haemophilus inﬂuenzae (NTHi; Duim et al., 1993; Yi and Murphy,
1997). The lack of M35-speciﬁc antibody binding to the surface of
the variant isolate implied that the majority of antibodies raised
in mice against M35 were speciﬁc for loop 3 (where the mutation
is located) and that loop 3 might be surface exposed. Such a result
would suggest that either the predicted folding of M35 was incor-
rect or that loop 3 is either partially or fully outside the channel
in M35, which would be highly unusual for this type of an outer
membrane porin.
The aims of this study were threefold. Firstly, to further inves-
tigate the surface accessibility of antibodies directed against M35,
speciﬁcally the loop 3 region. Secondly, to determine the bacteri-
cidal and opsonizing activity of M35-speciﬁc and loop 3-speciﬁc
antibodies in vitro. Thirdly, to determine the efﬁcacy of M35 as a
protective antigen in a mouse mucosal immunization pulmonary
clearance model (Kyd et al., 1998, 1999; Murphy et al., 1998).
MATERIALS AND METHODS
CLONING AND EXPRESSION OF M35-DERIVED PROTEIN CONSTRUCTS
Three recombinant proteins based on M35 were constructed: (1)
M35(ID78), the full M35 protein based on the gene from the
variant isolate ID78LN266; (2) L3DHFR, loop 3 with dihydrofo-
late reductase (DHFR) as a carrier protein; and (3) DHFR alone
as a control. M35(ID78) contains two amino acid substitutions
in comparison to the consensus M35 sequence, one of which
was found previously to be antigenically signiﬁcant (Easton et al.,
2005). In addition to these newly constructed recombinant pro-
teins, the consensus M35, the mature M35 (M35mat), and M35
without the loop 3 region (M35loop3−) were also used in this
study (Easton et al., 2005). The relative structures of the recombi-
nant proteins used in this study are represented diagrammatically
in Figure 1. All recombinant proteins expressed a 6×His tag
sequence at the N-terminal and were produced by expression
in M15 [pRep4] Escherichia coli (Qiagen) with puriﬁcation by
nickel-nitrilotriacetic acid column chromatography according the
manufacturer’s protocol for this expression system under dena-
turing conditions (8M urea). M35 and the variant forms were
FIGURE 1 | Diagramatic representation of the structure of M35 and the
M35-derived recombinant proteins. (A) Schematic of M35 showing the
relative lengths of the external loops. (B) Relative sequence inclusions of
the recombinant protein constructs. LP, leader peptide and X, amino acid
substitution. M35mat does not include the leader peptide; M35 is the full
sequence including the leader peptide; M35(ID78) includes the two amino
acid substitutions present in M35 from isolate ID78LN266 when compared
to the consensus, which are valine to isoleucine at position 32 and glycine
to aspartic acid at position 133; M35loop3− does not include the loop 3
region; L3DHFR is the loop 3 region of M35 attached to the DHFR carrier.
.
refolded as previously described (Watanabe, 2002; Easton et al.,
2005).
M35(ID78) was cloned by amplifying the M35 gene sequence
from genomic DNA extracted from the ID78LN266 isolate of M.
catarrhalis, as described previously for the consensus M35 using
the pQE30 vector (Qiagen) (Easton et al., 2005).
L3DHFR was produced by amplifying the gene sequence coding
for the loop3 regionof theM35 gene fromgenomicDNAextracted
from the 4223 isolate of M. catarrhalis using primers DEM35L3R
(antisense) GCCCTGCAGATTGTTGGCACG and DEM35L3F
(sense) GCCAGATCTATTGATGACAGTGTTG. These primers
introduced SphI and Pst I restriction enzyme recognition sites at
either end of the PCR product that enabled directional insertion
into the vector. The pQE40 vector (Qiagen) was used because
this vector contains the coding sequence for DHFR immediately
preceding the multiple cloning site and the recombinant protein
produced therefore contains the carrier at the N-terminal end of
the construct.
PRODUCTION OF HYPERIMMUNE MOUSE SERUM
Antiserawas raised for eachof theM35-derivedproteins andwhole
killed M. catarrhalis in male BALB/c mice. Mice were immunized
intraperitoneally three times at weekly intervals with 10μg of
each of the M35-derived protein constructs or 108 whole killed
M. catarrhalis emulsiﬁed with an equal volume of incomplete
Freund’s adjuvant (IFA). The antibody concentration (total IgG)
was measured by enzyme linked immunosorbent assay (ELISA)
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against the speciﬁc antigen. The immunization experiments were
approved by the University of Canberra Committee for Ethics in
Animal Experimentation and the Central Queensland University
Animal Ethics Committee.
ENZYME LINKED IMMUNOSORBENT ASSAY
Enzyme linked immunosorbent assay was used to measure spe-
ciﬁc IgG and IgA as described previously (Kyd et al., 1999),
however the volumes were reduced to 50μL and the assay was
developed using Zymed® 3,3′,5,5′-tetramethylbenzidine (TMB)
single solution (Invitrogen). The ELISA plates were coated with
0.5μg of the relevant antigen for each group. The whole killed
4223 cells were sonicated prior to coating for the WKC group.
The serum and bronchoalveolar lavage (BAL) were serially diluted
starting at 1/5 and 1/2, respectively. The antibody concentration
was measured for each mouse individually against the same anti-
gen with which the mouse was immunized and the samples from
the non-immunized mice were tested for antibody against both
M35 and the whole M. catarrhalis cells. The limit of detection was
approximately 0.2μg/mL for IgG and 0.125μg/mL for IgA.
FLOW CYTOMETRY
Binding of antibodies raised against the M35-derived protein
constructs to the surface of M. catarrhalis cells was analyzed
by ﬂow cytometry. M. catarrhalis isolates 4223 and ID78LN266
were grown overnight on brain heart infusion agar (Oxoid) sup-
plemented with 5% deﬁbrinated horse blood, washed in ster-
ile PBS with 0.5% BSA and adjusted to a concentration of
1× 1010 CFU/mL using the optical density (OD) at 400 nm. One
hundred microliter aliquots of the cell suspensions were cen-
trifuged and resuspended in the mouse anti-serum diluted to
approximately 20μg/mLwith sterile PBSwith 0.5%BSAand incu-
bated for 1 h at 37˚C to allow the antibodies to bind. The bacteria
were centrifuged and resuspended in a 1/200 dilution of goat anti-
mouse IgG AlexaFluor488 (Molecular Probes, Invitrogen) and
incubated for 1 h at 37˚C. The labeled cells were washed twice
in sterile PBS before analysis with a ﬂow cytometer (Coulter XL-
MCL, Beckman Coulter). About 100,000 events were counted and
binding of antibodieswas assessed by observationof the curve shift
in comparison to bacteria exposed to serum from non-immunized
mice.
EVALUATION OF COMPLEMENT SENSITIVITY
The isolate 4223 was not used for the bactericidal and
opsonophagocytosis assays because, like many other M. catarrhalis
isolates, it is complement resistant. Five isolates from our collec-
tion that had originally been collected by nasopharyngeal swab
from healthy children with asymptomatic carriage were tested
because these isolates are more likely to be serum sensitive than
isolates taken from infection (Hol et al., 1995). To assess the
complement sensitivity of these isolates the culture and spot
test described by Verduin et al. (1995) was used. The isolates
were grown overnight with shaking at 37˚C in Mueller–Hinton
broth (Oxoid). The bacteria were pelleted by centrifugation and
resuspended in veronal buffered saline (VBS2+; 5mM barbitone,
145mM NaCl, 0.15mM CaCl2, 0.5mM MgCl2, pH 7.4). The con-
centrationwas adjusted to approximately 1.5 × 108 CFU/mLusing
the OD at 400 nm. One hundred microliter of this suspension
was then spread on 5% sheep agar plates (Oxoid) and allowed to
absorb. Fifty microliter of guinea pig serum, both active and heat-
inactivated (30min at 56˚C), was spotted in duplicate on to each
plate and the plates were immediately incubated at 37˚C. After
overnight incubation the bacterial growth within the spots was
evaluated. This assay was repeated twice and the 2:03KAL isolate
was chosen because of consistency in the active serum inhibiting
growth and the heat-inactivated serum not inhibiting its growth
to any detectable degree. M35 is very well conserved across diverse
isolates (Easton et al., 2005), however as this isolate had not been
included in our previous study, the expression of M35 and its
antigenic conservation with 4223 was conﬁrmed by western blot.
BACTERICIDAL ASSAY
The bactericidal activity of antibodies raised against the M35-
derived proteins was assessed using the method described by Mur-
phy et al. (1998). Serum samples from intraperitoneally immu-
nized mice were heat-inactivated by incubation at 56˚C for 30min
before use. The serum was also diluted with PBS to give an equiv-
alent concentration of antibody as determined by ELISA, which
was necessary because the purpose of the experiment was to com-
pare the bactericidal activity of the antibodies raised against the
different proteins rather than the efﬁcacy of immunization with
these proteins. The ﬁnal antibody concentration of each sample
was approximately 20μg/mL.
Moraxella catarrhalis isolate 2:03KAL was grown in brain heart
infusion (BHI) broth at 37˚C with shaking at 220 rpm until the
OD at 600 nm was approximately 0.2, indicative of early log-
phase growth. The early log-phase broth culture was diluted
1/4000 with sterile PCGM saline (3.26mM NaH2PO4, 12.8mM
NaHPO4, 125mM NaCl, 1.25mM CaCl2, 0.5mM MgCl2, 1%
gelatin). Twenty microliter of this cell suspension was added to
each well of the microtiter plate with 10μL of sterile PBS. Ten
microliter of heat-inactivated serum sample was added to each
well, with each serum sample being tested in triplicate. Serum
from mice immunized with whole formalin-killed M. catarrhalis
4223 cells (WKC) was included as a positive control. Control wells
without serum received sterile PBS instead of serum. The sam-
ples were mixed gently by pipetting and incubated for 30min at
room temperature to allow the antibodies present in the mouse
serum to bind to the bacteria. Ten microliter of guinea pig serum
was then added to each well as the complement source and the
cells were incubated for a further 30min at 37˚C to allow com-
plement mediated killing of the bacteria. No complement control
wells received sterile PBS instead of the guinea pig serum. Two
hundred microliter of sterile PCGM saline was added to each well
and 50μL aliquots were spotted on to CBA plates in duplicate to
enable quantiﬁcation of live bacteria. The plates were incubated
overnight and the number of colony forming units in each spot
was counted.
The bacterial counts were compared with the negative control
wells that did not have mouse serum, complement source or both.
Serum from non-immunized mice was also included as a nega-
tive control. A viability control was included that was titrated at
the beginning of the incubation period so that survival during the
incubation time could be assessed. A positive result is considered
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killing that reduces recovery to ≤50% of the recovery from the
negative control (Murphy et al., 1998).
OPSONOPHAGOCYTOSIS ASSAY
An assay to measure the ability of antibodies raised against the
M35-derived proteins to opsonize M. catarrhalis and thereby pro-
mote phagocytosis of the bacteria was developed with reference
to similar assays used to analyze opsonization of other species of
bacteria (Aase et al., 1995; Delvig et al., 1997a; Martinez et al.,
1999; Jomaa et al., 2005a). M. catarrhalis 2:03KAL was grown
overnight on CBA plates, harvested, washed twice in sterile PBS
and ﬂuorescently dyed with 5-chloromethylﬂuorescein diacetate
(CMFDA) using the method suggested by the manufacturer (Mol-
ecular Probes). Approximately 1 × 1010 CFU was harvested from
a CBA plate, washed in PBS, and resuspended in 400μL of 5μM
CellTracker Green CMFDA diluted in BHI media. The bacteria
were incubated for 30min at 37˚C, pelleted again by centrifuga-
tion, resuspended in 1mL BHI media, and again incubated for
30min at 37˚C. The bacteria were washed ﬁve times in Hank’s
buffered salt solution (HBSS) with 0.2% BSA and after the ﬁnal
wash their concentration was adjusted to 2× 108 CFU/mL by esti-
mation from the OD at 400 nm. Twenty microliter of the bacterial
suspension was mixed with 10μL of mouse serum and incubated
for 30min at 37˚C with gentle shaking (150 rpm). The serum
samples were diluted to approximately the same relative antibody
concentration as determined by ELISA (approximately 20μg/mL)
so that the results would reﬂect the opsonizing ability of the anti-
bodies rather than to differences associatedwith titer to the speciﬁc
antigens.
Ten microliter of guinea pig serum was added as an exogenous
complement source and the mixture was incubated for a further
15min at 37˚C with gentle shaking. Mouse macrophages (RAW
264.7)werewashed twicewithHBSS and oncewithHBSS contain-
ing Ca2+ and Mg2+ and the concentration of cells was adjusted
to 2.5× 106 cells/mL. Forty microliter of this macrophage sus-
pension was added to the bacterial suspension. The mixture was
incubated for 30min at 37˚C with gentle shaking to allow phago-
cytosis of the bacteria by the macrophages. The cells were diluted
with 200μL of HBSS with Ca2+ and Mg2+ with 0.2% BSA, 50μL
of 0.5mg/mL trypan blue was added to quench the ﬂuorescence of
extracellular bacteria and the cells were kept on ice before analysis
using a ﬂow cytometer (Beckman Coulter XL-MCL).
The relative ﬂuorescence of the macrophages was used to assess
the degree of phagocytosis in each sample. A higher percent-
age of ﬂuorescent macrophages indicated a higher percentage of
these cells had phagocytosed bacteria. Controls were included that
received buffer instead of the mouse serum and serum from either
non-immunized mice or mice immunized with whole killed M.
catarrhalis 4223 (WKC) were included as negative and positive
controls, respectively.
MOUSE LUNG CHALLENGE MODEL WITH MUCOSAL IMMUNIZATION
The mucosal immunization regime consisted of an intra-Peyer’s
patch (IPP) immunization followed 14 days later by an intra-
tracheal (IT) boost, following the method developed by Kyd et al.
(1999). Each mouse received 10μg of recombinant protein anti-
gen or 108 CFU of formalin-killed bacteria in each immunization.
The mice were immunized with one of the following antigens:
(1) whole killed M. catarrhalis 4223; (2) M35; (3) M35mat; (4)
M35loop3−; (5) L3DHFR; and (6) DHFR. Five male BALB/c mice
were included in each immunization group and a non-immunized
control group was included in each experiment. Protein concen-
trations were determined with a micro BCA assay kit (Pierce) and
adjusted to 2mg/mL. Proteins were concentrated using Amicon
Ultra-15 Centrifugal Filter Units (Millipore) with a molecular
weight limit of 5 kDa and ﬁnal adjustments were made by dilution
with 10mM Tris–Cl, pH 7.4. As the M35-derived proteins precip-
itate without the presence of a denaturing agent or detergent, urea
was added to ﬁnal concentration of urea of 2.5M.
Pulmonary challengewith 1× 107 CFU liveM. catarrhalis 4223
was carried out 21 days after the IPP immunization, following
the protocol described by Kyd et al. (1999). This experiment
was undertaken with the approval of the Central Queensland
University Animal Ethics Committee.
STATISTICAL ANALYSIS
For the opsonophagocytosis assay triplicate values for the percent-
age of macrophageswith ﬂuorescence greater than the background
for each sample were averaged and compared by one-way analy-
sis of variance (ANOVA) with Tukey’s multiple comparison test.
Values for bacterial recovery and antibody concentrations for each
immunization group were compared to the non-immunized con-
trol group using a one-way ANOVA followed by Bonferroni’s
multiple comparison test. Correlation of results was assessed using
a Pearson’s test. All analyses were performed using GraphPad
Prism 4.0b.
RESULTS
ANTIBODY-BINDING TO SURFACE EPITOPES OF M35
Surface accessibility of the recombinant M35 proteins and loop
3 of M35 was investigated by determining the ability of anti-
body to bind to surface epitopes of M35 in M. catarrhalis isolates
4223 and ID78LN266 by ﬂow cytometry (Figure 2). Antibodies
raised against M35 bound to the cell surface of M. catarrhalis as
demonstrated by a small right-shift in the relative ﬂuorescence
compared to the control non-immune serum. While this shift
was small, it was reproducible and consistent with our previous
results (Easton et al., 2005). Antibodies raised against M35(ID78)
and M35loop3−, respectively, caused similar sized right-shifts to
that seen with anti-M35 serum. Antibodies raised against L3DHFR
and DHFR caused smaller right-shifts than those seen with the
anti-M35 serum. The lack of difference between the right-shifts
seen with L3DHFR and DHFR antisera, indicates that any bind-
ing was not due to loop 3-speciﬁc recognition by the serum
antibodies.
The binding of antibodies toM. catarrhalis differed between the
strains of bacteria used.Antibodies raised inmice immunizedwith
isolate 4223 demonstrated a greater ability to bind to whole killed
cells of strain 4223 than that seen when tested against whole killed
cells from strain ID78LN266. This may indicate that these two
isolates differ substantially in the availability of outer membrane
protein epitopes that are targeted by the antibodies. It was also
noted that the background staining with naïve serum was higher
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FIGURE 2 | Flow cytometry histograms showing the relative
fluorescence of M. catarrhalis ID78LN266 incubated with antibodies
raised against the M35-derived constructs. The strain is indicated in
the lower right-hand corner of each panel and the antigen against
which the anti-serum was raised is indicated in the top left-hand
corner of each panel. WKC; whole killed cell, formalin-killed
M. catarrhalis 4223. The gray histograms represent non-immune control
serum.
with isolate ID78LN266 than isolate 4223 (data not shown), sug-
gesting that isolate ID78LN266 may express surface components
with epitope sequences homologous to the normal ﬂora of the
mice. This difference between the strains may partly explain the
lack of signiﬁcant binding between the naïve sera andM35-speciﬁc
antibodies to isolate ID78LN266 in our previous study (Easton
et al., 2005).
BACTERICIDAL ACTIVITY OF M35-SPECIFIC ANTIBODIES
In an in vitro bactericidal assay, a greater than 50% killing of
bacteria was achieved using anti-serum raised against the whole
formalin-killed M. catarrhalis cells (WKC; Figure 3). None of the
antisera raised against loop 3 or the M35-derived proteins were
bactericidal (Figure 3).
ENHANCEMENT OF OPSONOPHAGOCYTOSIS BY M35-SPECIFIC
ANTIBODIES
The ability of antibodies raised against each of the recombi-
nant proteins to opsonize and therefore enhance phagocytosis
of live M. catarrhalis cells was tested by determining the per-
centage of macrophages that had phagocytosed ﬂuorescently
labeled live M. catarrhalis. Using ﬂow cytometric analysis the
ﬂuorescent intensity of the macrophages was assessed follow-
ing incubation with ﬂuorescently labeled bacteria in the pres-
ence or absence of antisera (Figure 4). Bacteria exposed to the
4223 WKC anti-serum as a positive control were readily phago-
cytosed with nearly 50% (48± 1.3%) of macrophages showing
greater than background ﬂuorescence (p < 0.001). An average
of 9.8± 0.2% of macrophages phagocytosed bacteria that were
exposed to serum from non-immunized mice and this was a
similar percentage to the control sample exposed to sterile PBS
instead of serum (10.8 ± 0.84%). Antibodies against L3DHFR
and DHFR both failed to enhance phagocytosis, with results of
11.8± 0.6 and 10.7± 0.4%, respectively. Antibodies raised against
M35, M35(ID78), and M35loop3− all enhanced phagocytosis
with a small signiﬁcant increase in ﬂuorescence of 15.6± 0.8%
(p < 0.05), 17.2± 1.6% (p < 0.01), and 16.4± 2.3% (p < 0.01),
respectively (Figure 4).
FIGURE 3 | Bacterial recovery after bactericidal killing of M. catarrhalis
2:03KAL mediated by antibodies raised against the M35-derived
antigens. Values are the mean of triplicate assays each titrated in duplicate.
Error bars show SD.The value equivalent to 50% killing of the cells exposed
to serum from non-immunized mice is indicated by the dotted line. Assay
controls are unshaded.
BACTERIAL RECOVERY FROM MOUSE LUNGS AFTER CHALLENGE WITH
LIVE M. CATARRHALIS
The effect of mucosal immunization with each M35-derived con-
struct was assessed by quantiﬁcation of M. catarrhalis recovered
from the lungs of mice 4 h after challenge by intra-tracheal inocu-
lation with live bacteria. The quantity of live bacteria recovered
from the BAL ﬂuid, lung homogenate and in total from mice
mucosally immunized with each antigen is shown in Figure 5.
When compared to thenon-immunizedmice thenumber of bacte-
ria recovered from mice mucosally immunized with the formalin-
killed M. catarrhalis 4223 cells (WKC) were signiﬁcantly lower
in both the BAL (p < 0.001) and lung homogenate (p < 0.01).
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FIGURE 4 | Percentage of macrophages with enhanced fluorescence
due to phagocytosis of M. catarrhalis 2:03KAL opsonized by antibodies
raised against the M35-derived antigens. Values are the mean of
triplicate assays. Error bars show SD. Asterisks indicate statistical
signiﬁcance compared to the non-immunized control group: *p < 0.05,
**p < 0.01, ***p < 0.001. The assay control is unshaded.
The bacterial recovery in the lung homogenate from mice mucos-
ally immunized with M35, M35(ID78), and M35loop3− was also
signiﬁcantly lower than from the non-immunizedmice (p < 0.01),
however in the BAL ﬂuid, enhancement of bacterial clearance
only reached signiﬁcance when M35(ID78) was the immuniz-
ing antigen (p < 0.01). When BAL and lung values were added
to give total bacterial recovery (Figure 5A) all three groups [M35,
M35(ID78), and M35loop3−] had signiﬁcantly lower numbers of
bacteria recovered in total than in the non-immunized control
group (p < 0.01). Bacterial recovery from the mice immunized
withM35mat, L3DHFR, andDHFRdid not differ signiﬁcantly from
the non-immunized control groups in either the BAL ﬂuid, lung
homogenate, or total recovery (p > 0.05).
ANTIBODY TITER AFTER MUCOSAL IMMUNIZATION
IgG and IgA concentrations in the BAL ﬂuid of immunized mice
were very low and were undetectable in many samples (Table 1).
The results from individual mice were found to be variable within
the immunization groups, as indicated by the large SDs shown in
Table 1. The concentration of IgG in the BAL tended to reﬂect the
concentration in the serum for each individual animal. The non-
immunized mice did not have any detectable anti-M. catarrhalis
antibody. Serum IgG antibody to loop 3 was very low when
detected and was undetectable in most of the mice immunized
with L3DHFR and none of those immunized with DHFR (Table 1).
WHITE BLOOD CELL RECOVERY FROM MUCOSALLY IMMUNIZED MICE
The recruitment of white blood cells to the lungs is associated
with both innate and acquired immune responses to infection.
In general, the total white blood cells recovered at 4 h post chal-
lenge is signiﬁcantly higher in the WKC immunized groups when
compared with the non-immune groups and this pattern was
FIGURE 5 | Bacterial recovery after 4 h challenge with live
M. catarrhalis. (A)Total recovery, (B) recovery from lung homogenate, and
(C) recovery from BAL ﬂuid. Boxes represent the 25th–75th percentile,
the line through the box indicates the median and the whiskers extend
between the highest and lowest values. Asterisks indicate statistical
signiﬁcance compared to the non-immunized control group: *p < 0.05,
**p < 0.01, ***p < 0.001.
replicated in this study (Figure 6A). The total number of white
blood cells recruited to the lungs and counted in the BAL was
highest in the L3DHFR group (p < 0.001; Figure 6A). The most
abundant cell type were neutrophils (Figure 6B) followed by
monocytes/macrophages (Figure 6C) and in general the propor-
tions followed the same trend as the total white blood cell counts
for each group (Figure 6A), with the exception that there was sig-
niﬁcantly more monocyte/macrophage cells recovered from the
WKC group compared to the non-immunized mice (p < 0.01).
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Table 1 | Specific antibody levels in serum and BAL after mucosal
immunization.
Immunization
groupa
Serum IgG
(μg/mL)b
BAL IgG
(μg/mL)
BAL IgA
(μg/mL)
Non-immune n.d.c n.d. n.d.
WKC 2.25± 1.07 0.34± 0.34 n.d.
M35 16.4± 25.6 0.25± 0.75 0.01± 0.04
M35mat 54.4± 42.6 0.49± 0.45 0.01± 0.03
M35(ID78) 75.8± 47.8 1.23± 0.95 0.02± 0.04
M35loop3− 52.9± 62.1 0.60± 0.65 n.d.
L3DHFR 0.064± 0.14 n.d. n.d.
DHFR n.d. n.d. n.d.
aThe antibody concentration was measured for each mouse individually against
the same antigen with which the mouse was immunized and the samples from
the non-immunized mice were tested for antibody against both M35 and the
whole M. catarrhalis cells. DHFR was assayed against L3DHFR.
bValues are mean and SD.
cNot detected.
CORRELATION BETWEEN BACTERIAL CLEARANCE AND
OPSONOPHAGOCYTOSIS
To determine if there was a direct relationship between the
ability of the animals to clear the infection challenge and the
opsonophagocytosis results, a Pearson’s test was conducted. There
was a direct and signiﬁcant correlation (Figure 7) between the
total bacterial recovery from mice in each immunization group
(Figure 5A) and the enhancement of opsonophagocytosis medi-
ated by serum antibody raised against the same immunization
antigens (Figure 4; p = 0.001).
DISCUSSION
M35 is an OMP from M. catarrhalis that we have been investi-
gating for its functional role and potential as a vaccine antigen.
Our initial characterization of M35 suggested that it possesses the
desired characteristics of a vaccine antigen in that it is highly con-
served, surface exposed, and immunogenic in an animal model
(Easton et al., 2005). Our previous study also indicated that the
loop 3 region of M35 was immunodominant over the remain-
der of the protein when mice were immunized with recombinant
refolded M35 protein and raised the possibility that this loop may
not be accessible to antibodies in the native protein expressed on
the surface of the bacteria. Thus a situation may exist where the
majority of antibodies produced against M35 are not effective due
to an inability to bind to the protein on the cell surface. This would
also be also consistent with previous observations relating to other
porin proteins such as the loop 3 of the E. coli OMP F porin pro-
tein which has a major B cell region within the loop 3 domain
(Williams et al., 2000; Yamashita et al., 2008). To investigate this
hypothesis we have assessed the functional activity of antibodies
speciﬁc to M35 and its loop 3 region.
This study has established that whilst at least some of the anti-
bodies raised against the full M35 protein are able to bind to the
protein on the cell surface, those speciﬁc for loop 3 do not bind
a surface accessible epitope. The functional assays have demon-
strated that while M35-speciﬁc antibodies were not bactericidal,
FIGURE 6 |The counts of white blood cells in the BAL fluid. (A)Total
WBC, (B) total neutrophils and (C) total monocytes. Values shown are
log10cell/mL. Boxes represent the 25th–75th percentile, the line through the
box indicates the median and the whiskers extend between the highest
and lowest values. Asterisks indicate statistical signiﬁcance compared to
the non-immunized control group: *p < 0.05, **p < 0.01, ***p < 0.001.
antibodies to intact M35 constructed proteins were opsonizing in
vitro. Loop 3-speciﬁc antibodies were neither opsonizing nor bac-
tericidal, providing further evidence that antibodies speciﬁc for
this immunodominant epitope are unlikely to be effective against
infection. While this is the longest of the external loop regions,
the lack of surface recognition, or opsonizing activity by loop 3-
speciﬁc antibody supports the proposed structural model that this
loop folds into the channel formed by the protein (Easton et al.,
2005). Bactericidal activity has beenused to assess functional activ-
ity for other M. catarrhalis antigens. Human antibodies to MID,
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FIGURE 7 |The correlation between average total bacterial recovery
after mucosal immunization and the enhancement of phagocytosis of
M. catarrhalis due to opsonization by antibody raised against the
same antigen.
UspA1, and UspA2 (Tan et al., 2006) and mouse antibodies dLOS,
CD, and UspA (Hu et al., 2004) have been shown to be bacteri-
cal in vitro. Therefore in the current study, antibody to antigens
other than M35 were responsible for the bacterical killing by WKC
antisera.
The efﬁcacy of potential vaccine antigens against M. catarrhalis
has been modeled using the murine mucosal immunization –
pulmonary challenge model, in which effective immunization
enhances the clearance of live bacteria from the lungs of mice
(Murphy et al., 1998; Kyd et al., 1999). At present there is no
correlate of protection for M. catarrhalis in this model and it is
unknown whether antigens found to be effective in this model
will also be effective in humans (Murphy, 2005, 2009). Attempts
to determine the mechanism of protection in the mouse model
have investigated the quantity, type and in vitro bactericidal capac-
ity of antibodies produced by the mice, however none of these
parameters has been shown to be deﬁnitive correlates of protec-
tion (Murphy et al., 1998; Kyd et al., 1999). For example, Murphy
et al. (1998) found that while mucosal immunization led to the
production of bactericidal antibody, intramuscular immunization
did not, but both routes were similarly effective at enhancing clear-
ance of the bacteria, suggesting that the bactericidal capacity of the
antibodies was not necessarily a correlate of protection in an acute
infection mode identical to that described in the current study.
Differences between the naïve and immune-induced inﬁltration
of phagocytic cells can be an indicator of antigen speciﬁc upreg-
ulation of the host’s immune response to the infection. Therefore
we hypothesized that immunization would enhance Fc-mediated
phagocytic removal of live bacteria via enhanced opsonization.
Sera from WKC immunized mice demonstrated the most signif-
icant opsonizing activity and these mice also showed the greatest
level of enhanced bacterial clearance in the lung infection study.
In contrast, the L3DHFR immunization was the least effective and
the antisera was not opsonizing. Analysis of the correlation of
the opsonic capacity of M35-speciﬁc antibodies with bacterial
clearance in vivo showed a linear relationship, indicating a direct
correlationbetween the twomeasures. This is an importantﬁnding
in that it raises the question of whether opsonizing antibodywould
also be protective in humans, or whether it only appears to be pro-
tective in the mice due to the short time-frame of the challenge
model and perhaps even just for this antigen. Also of interest is
that there does not appear to be a relationship between the num-
ber cells recruited to the lung following challenge and clearance.
However, if opsonizing antibodies are not induced a large cellular
inﬂux does not result in enhanced bacterial clearance from the
lung. This is most striking for the L3DHFR data.
A hallmark of respiratory infections is the rapid recruitment of
white cells to the bronchial space following infection. This recruit-
ment into the lung is in response to bacterial lipopolysacharide
and a range of inﬂammatory mediators that are released by res-
ident phagocytes and endothelial cells of the bronchus (Dunkley
et al., 1995). Immunization with antigens from NTHi, Strepto-
coccus pneumoniae and Pseudomonas aeruginosa have previously
been reported to enhance the recruitment of white cells (both
neutrophils and monocytes) when the lung is challenged with live
microbes (Buret et al., 1994; Foxwell et al., 2001; Jomaa et al.,
2005b). Furthermore, this recruitment is antigen dependent with
immunization by WKCs normally be the most effective (Jomaa
et al., 2005b). However, in a previous study of M. catarrhalis, we
did observe that immunization with puriﬁed OMP CD was as
effective asWKC in enhancing the recruitment of white cells to the
lung (Murphy et al., 1998). In the current study we observed that
whilst WKC immunization was effective in enhancing the recruit-
ment of monocytes to the lung, L3DHFR was actuallymore effective
and enhanced the recruitment of neutrophils as well. The mecha-
nism by which immunization is able to enhance the recruitment of
white cells to the lung is most likely T cell dependent (Khader et al.,
2009). It is thought that antigen speciﬁc T cells are generated in the
gut associated lymphoid tissue following immunization and home
to the lung via the common mucosal immune system (Otczyk and
Cripps, 2010; Clancy and Dunkley, 2011) where they secrete a
range of cytokines and chemokines that result in the recruitment
of further neutrophils (Clancy andDunkley,2011). In this scenario
a plausible explanation for the signiﬁcantly enhanced recruitment
of cells after immunization with L3DHFR would be the presence of
T cell epitopes within the construct.
Although the role of opsonizing antibody has been speculated
upon (Murphy et al., 2003), the only study demonstrating the
development of oponizing antibody showed that antisera from 11
children with M. catarrhalis otitis media had increased opsonic
activity in convalescent sera (34.6± 27.1) compared to acute sera
(15.5± 6.7; p < 0.05; Faden et al., 1994). We are not aware of
any other studies that have shown a correlation between anti-
body responses to a M. catarrhalis antigen and opsonic activity in
the absence of bactericidal activity. It will be important to test in
future studies whether this is speciﬁc to immunization with the
M35-derived proteins or whether enhancement of in vitro phago-
cytosis is also correlated with protection after immunization with
other M. catarrhalis antigens. A similar observation was reported
for N. meningitidis, where the majority of PorB-speciﬁc IgG was
not bactericidal but was strongly opsonic (Delvig et al., 1995, 1996,
1997b).
Anti-M35 serum demonstrated weak binding to M35loop3−,
no binding to DHFR, weak binding to M35(ID78) but strong
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binding to both M35 and L3DHFR. (data not shown). Anti-L3
sera showed strong recognition of the M35 proteins, demonstrat-
ing that while there are conformational differences between the
L3 regions of the whole M35 and the L3DHFR construct, there is
cross recognition of the epitopes in common between the peptide
and the recombinant whole protein. Antibodies speciﬁc for M35,
M35(ID78), and M35loop3− were all able to bind to the surface
of the bacterium, meaning that the presence, absence, or alter-
ation of loop 3 did not affect the recognition of surface epitopes
of M35. However, loop 3-speciﬁc antibodies were unable to bind
to M35 on the surface of M. catarrhalis, supporting the prediction
that the loop 3 region would not be accessible to antibodies, as it
was predicted that it folded into the porin channel (Easton et al.,
2005). Analysis of the in vitro opsonophagocytic activity of the
M35-speciﬁc antibodies revealed that antibodies speciﬁc for the
loop 3 region were not able to enhance phagocytosis, presumably
due to their inability to bind on the cell surface. Antibodies raised
againstM35,M35(ID78), andM35loop3− were all able to enhance
in vitro phagocytosis, demonstrating that it was antibody directed
at the surface region that was responsible for the increase in phago-
cytosis and also that deletion of loop 3 did not create alterations to
the protein that affected production of antibody with opsonizing
activity. It therefore appears that, unlike the N. meningitidis PorB
where the immunodominant region was in loop 1 (Delvig et al.,
1995, 1996, 1997b) and surface exposed, the majority of antibod-
ies raised against M. catarrhalis M35 are against loop 3 and are
not opsonizing due to speciﬁcity for an apparently hidden loop
region.
Preliminary studies with the native protein had demonstrated
the efﬁcacy of M35 as a protective antigen when used in mucos-
ally immunized mice prior to pulmonary challenge with live M.
catarrhalis (unpublished data). Since our subsequent investiga-
tions had suggested that the majority of antibodies produced
following immunization were directed at loop 3, it was hypothe-
sized that immunizationwith loop3 alonewouldnot beprotective.
Mice immunized with M35, M35(ID78), and M35loop3− cleared
signiﬁcantly more of the bacteria from their lungs than the non-
immunized control mice, indicating that deletion of the loop 3
region from the protein did not reduce, or enhance, the efﬁcacy
of the M35-speciﬁc response to infection. Mice mucosally immu-
nized with the loop 3 peptide were not able to enhance clearance
of the bacteria, however, these mice produced very low levels of
L3DHFR-speciﬁc IgG detectable only in the sera and no IgG or IgA
was detected in the BAL. However, mice immunized with M35
that contains an antigenically different loop 3 M35(ID78) (Easton
et al., 2005) or had the loop 3 region deleted (M35loop3−) had
similar immune efﬁcacy against infection, indicating that anti-
body generated against loop 3 from whole protein immunization
was not involved in M35-speciﬁc bacterial clearance. Therefore,
while clearance of M. catarrhalis in the acute mouse lung chal-
lenge model could be enhanced by mucosal immunization with
M35, this was independent of loop 3 as predicted. Studies with
NTHi OMP P5 found that the fourth surface exposed region of the
P5 antigen from NTHi was immunodominant over the remainder
of the protein and not protective, however, immunization with
the third surface exposed region of P5 was protective (Novotny
and Bakaletz, 2003). It is possible that a similar pattern could exist
with M35, suggesting further investigation of the antigenic roles
of speciﬁc surface loops of M35 is warranted.
CONCLUSION
This study has conﬁrmed our prediction that the majority of
antibodies raised against M35 that were speciﬁc for loop 3 are
ineffective and unlikely to be associated with immune protection
against infection. The study has found that there was a corre-
lation between opsonizing antibodies associated with enhanced
phagocytosis and in vivo enhancement of bacterial clearance in
mucosally immunized mice. Immunization with M35 with or
without loop 3 was effective in enhancing clearance in the mouse
pulmonary challenge model, suggesting that the enhancement of
opsonophagocytosis due to antibodies to other surface epitopes
contributed to this response. The study suggests that opsonic
antibodies are potentially important for enhanced clearance and
the role of opsonic antibody to M. catarrhalis should be further
investigated for other antigens.
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